DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylation agents

Brian J. Glassner1,7, Geert Weeda2,7, James M. Allan1, Jose1 L.M. Broekhof2, Nick H.E. Carls2, Ingrid Donker3, Bevin P. Engelward4, Richard J. Hampson1, Remko Hersmus3, Mark J. Hickman1, Richard B. Roth1, Henry B. Warren2, Mavis M. Wu1, Jan H.J. Hoeijmakers2 and Leona D. Samson1,5

1 Department of Cancer Cell Biology, Toxicology Division, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA,
2 Department of Cell Biology and Genetics, Medical Genetics Center and Comparative Medicine, Harvard Medical School, 665 Huntington Avenue, Boston, MA 02115, USA,
3 Department of Pathology, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands and
4 Center for Animal Resources and Environmental Health, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
5 These authors contributed equally to this work

We have generated mice deficient in O6-methylguanine DNA methyltransferase activity encoded by the murine Mgmt gene using homologous recombination to delete the region encoding the Mgmt active site cysteine. Tissues from Mgmt null mice displayed very low O6-methylguanine DNA methyltransferase activity, suggesting that Mgmt constitutes the major, if not the only, O6-methylguanine DNA methyltransferase. Primary mouse embryo fibroblasts and bone marrow cells from Mgmt –/– mice were significantly more sensitive to the toxic effects of the chemotherapeutic alkylation agents 1,3-bis(2-chloroethyl)-1-nitrosourea, streptozotocin and temozolomide than those from Mgmt wild-type mice. As expected, Mgmt-deficient fibroblasts and bone marrow cells were not sensitive to UV light or to the crosslinking agent mitomycin C. In addition, the 50% lethal doses for Mgmt –/– mice were 2- to 10-fold lower than those for Mgmt +/+ mice for 1,3-bis(2-chloroethyl)-1-nitrosourea, N-methyl-N-nitrosourea and streptozotocin; similar 50% lethal doses were observed for mitomycin C. Necropsies of both wild-type and Mgmt –/– mice following drug treatment revealed histological evidence of significant ablation of hematopoietic tissues, but such ablation occurred at much lower doses for the Mgmt –/– mice. These results demonstrate the critical importance of O6-methylguanine DNA methyltransferase in protecting cells and animals against the toxic effects of alkylation agents used for cancer chemotherapy.

Introduction
DNA repair plays an important role in protecting genomes from insults inflicted by certain endogenous metabolites, by agents in the environment and, for a significant number of individuals, by cancer chemotherapeutic agents. Alkylation compounds are particularly cytotoxic, making them good chemotherapeutic agents, but they are also mutagenic and carcinogenic, detracting from their long-term clinical benefits. It is generally accepted that in cultured mammalian cells the DNA alkylation repair protein O6-methylguanine (O6-MeG) DNA methyltransferase (MTase) provides protection against such toxic and mutagenic effects of chemotherapeutic alkylation agents (Erickson et al., 1980; Samson et al., 1986; Barrows et al., 1986; Remack et al., 1987; Zolotovskaya et al., 1989; Tano et al., 1990, 1997; Kaina et al., 1991; Wu et al., 1991; Harris and Margison, 1993). O6-MeG DNA MTases repair alkylation damage via an unusual suicide mechanism involving irreversible transfer of alkyl DNA lesions to an internal cysteine residue (Lindahl et al., 1982, 1988). However, because this particular DNA repair protein is expressed at very different levels in mammalian tissues (Grafstrom et al., 1984; Pegg, 1984; Montesano et al., 1985; Pegg et al., 1985; Gerson et al., 1986; Moritz et al., 1995), varying by up to 100-fold, it has been difficult to predict from such in vitro tissue culture experiments the precise role of O6-MeG DNA repair MTase in protecting whole animals from chemotherapeutic alkylation agents. Furthermore, many of these agents produce DNA damage that are substrates for several different DNA repair pathways, hence, the relative contribution of each repair pathway may differ between alkylation agents and between tissues.

Chloroethyl nitrosourea (CNU) alkylation agents such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) induce numerous DNA lesions including highly cytotoxic DNA interstrand crosslinks. These crosslinks are formed via an intermediary O6-chloroethyl group and are thought to interfere with DNA replication (Ludlum, 1990); the repair of such O6-chloroethyl groups by the O6-MeG DNA MTase protein prevents DNA crosslink formation and thus provides protection against the cytotoxic effects of such agents (Erickson et al., 1980; Robins et al., 1983; Samson et al., 1986; Brent et al., 1987; Brent and Remack, 1988). Indeed, O6-MeG DNA MTase levels in cultured mammalian cells correlate with resistance to CNU alkylation agents (Erickson et al., 1980; Tsujimura et al., 1987; Lindahl et al., 1988; Mineura et al., 1990; Moritz et al., 1995; Wang et al., 1996; Phillips et al., 1997).

BCNU and other CNUs are used to treat a variety of tumors, in particular pediatric and adult gliomas, as well as cancers of the lymph, breast, lung and gastrointestinal (Broder and Rall, 1972; Carter et al., 1972; Schabel, 1976; Walker et al., 1978; Goldin and Schabel, 1981; Colvin, 1993). However, the success of such treatments is limited by severe myelosuppression, as well as lung toxicity (Schabel, 1976). Such myelosuppression is almost certainly due to the fact that bone marrow tissue has very low levels of O6-MeG DNA MTase and 3-methyladenine DNA glycosylase activities relative to other tissues (Gerson et al., 1986; Moritz et al., 1995; Glassner and Samson, unpublished results); indeed, introduction of the human O6-MeG DNA MTase gene, MGMT, into murine bone marrow cells significantly enhances resistance to chemotherapeutic...
Materials and methods

Reagents

pBluescript and a 129SV λ-fxII mouse genomic library were from Stratagene (La Jolla, CA). plS301 was from Invitrogen (San Diego, CA), E14 embryonic stem (ES) cells were kindly provided by A.Berns and Hte Rieke (Netherlands Cancer Institute, Amsterdam, The Netherlands). The neo and HSV-tk expression cassettes (Tbybulewicz et al., 1991) were subcloned from modifications of plasmids pPGK-NEO and pBS-PGK-TK-A, respectively (from D.Huszar, GenPharm International, Mountain View, CA). PCR primers were from Ransom Hill Bioscience (Ramona, CA). BCNU and temozolomide were from J.Taylor (National Cancer Institute, Bethesda, MD). N-methyl-N-nitro-N-nitrosoguanidine (MNGNG), MNU, mitomycin C (MMC), STZ and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide were from Sigma (St Louis, MO). Wild-type mice ([129×C57/dJ)]2F1) were from Jackson Laboratories (Bar Harbor, ME). Minimal essential medium alpha (α-MEM) and LIF was from Life Technologies (Grand Island, NY), MethoCult™ GF from Stem Cell Technologies (Vancouver, BC, Canada), and fetal bovine serum from HyClone Laboratories (Logan, UT).

Mgmt gene knockout targeting vector

The 129SV λ-fxII mouse genomic library was screened using a 32P-labeled PCR fragment that spanned Mgmt exon 5 (Shiraiishi et al., 1992). An ~1 kb NotI insert from a positive clone was subcloned into pBluescript to generate pBSMT42. The Mgmt gene targeting construct pMT42-ΔE5-NEO-TK (Figure 2B) was engineered from pBSMT42 in multiple steps. Briefly, two BamHI sites present in the neo cassette of pPGK-NEO were removed and an Xhol-MluI fragment containing this modified neo cassette was subcloned into pLSl-κB to generate pSL-PGK-NEOII. The larger NotI–NruI fragment of pBSMT42 (Figure 2B) was subcloned into a plS301 plasmid lacking an internal BamHI site to generate pSL-MT42-ΔBam. The smaller NotI–NruI pBSMT42 fragment served as a probe source. The positively selectable BamHI-MluI neo marker from pSL-PGK-NEOII was cloned into the BamHI–MluI exon 5 region of pSL-MT42-ΔBam, generating pSLMT2-ΔE5-NEO. An HSV-Δ containing NotI fragment from pBS-PGK-TK-A–NotI (Engelward et al., 1996) was cloned into the unique NotI site of pSLMT2-ΔE5-NEO, thus allowing for negative counter-selection against random integration events, to generate the final Mgmt knockout targeting construct pMT42-ΔE5-NEO-TK.

Generation of Mgmt knockout ES cells and mice

An aliquot of 20 µg of an ~12 kb HindIII fragment (from pMT42-ΔE5-NEO-TK) was electroporated into E14 ES cells as described (Engelward et al., 1997). G418- and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil-resistant clones were expanded and frozen at ~80°C (Engelward et al., 1997). Homologous recombinant ES cell clones were identified by Southern blot analysis (Asubel et al., 1994) using a 32P-labeled BagII–BamHI probe fragment (Figure 2B) and 10–15 karyotypically normal ES cells were injected into C57BL/6 blastocysts and implanted into pseudo-pregnant female CB6 mice; male chimeras were bred with C57BL/6 females and germline transmission was determined by transmission of the agouti coat color (data not shown).

Mgmt genotyping

Genomic DNA isolated from mouse liver ( Laird et al., 1991) was BamHI digested, then subjected to Southern blot analysis using a 32P-labeled BagII–BamHI probe fragment (Figure 2B). Genomic DNA from ear punches (Chen and Evans, 1993) was subjected to multiplex PCR analysis using primers P1, P2, and P3. Primers P1 (5′-GCGACTTTCTTCTTTCAACCTTGGA-3′) and P3 (5′-CCCCAGACACTTGGCTGCT-3′) detect the wild-type Mgmt allele (542 bp); primers P2 (5′-GTTGGGAGATTAGATATATGCGTCT-3′) and P3 detect the targeted Mgmt∆neo allele (409 bp) (Figure 2B).

Determining MTagE activity levels

Mouse liver extracts were prepared as described (Moritz et al., 1995). ES cells and mouse embryo fibroblasts (MEFs) were washed in phosphate-buffered saline (pH 7.3), resuspended in 100–300 µl MTagE buffer (50 mM HEPES, pH 7.8, 10 mM DTT, 1 mM EDTA, 5% glycerol), sonicated twice, the lysate cleared by centrifugation and aliquots stored at ~80°C. 6-MeG DNA MTase activity was determined by a rapid assay (Margison et al., 1985), using Micrococcus luteus DNA methylated with [3H]MNU (18 or 0.9 Ci/µmol; Amersham, UK) as described (Demple et al., 1983; Karren et al., 1979). DNA concentration in tissue extracts was determined using Hoescht 33258 fluorescence (Gerson et al., 1986) and protein concentration using the Bio-Rad Bradford (Bradford, 1976) Protein Assay (Richmond, CA).

Growth inhibition of MEs by chemotherapeutic alkylating agents

Primary MEs from 13.5-day-old mouse embryos were generated and maintained as described (Freshney, 1994). Cells were washed before and after drug treatment in phosphate-buffered saline. Drug exposure was in serum-free medium for 1 h. Cell exposure to UV was in 0.1 ml phosphate-buffered

Alkylating agents used in this study. *Agents that are used clinically as chemotherapeutics. The shaded box areas indicate the alkyl group transferred to DNA.
containing 10 ng/ml interleukin-3, 10 ng/ml interleukin-6, 50 ng/ml stem cell factor and 3 mg/ml erythropoietin) and duplicates plated in 35 mm dishes. After 10–12 days, colonies of ≥50 cells were counted and the surviving fraction determined using untreated duplicate cultures processed similarly.

*p* 50% lethal dose (LD*₅₀*) determinations

Six- to eight-week-old mice were given an i.p. injection at drug concentrations chosen based on previous reports as follows: BCNU, Thompson and Larson (1972); STZ, Iwasaki et al. (1976); MMC, Kinoshita et al. (1971); MNU, Sakumi et al. (1997). The treatment regime followed the recommendations of Deichmann and LeBlanc (1943), i.e. one mouse was treated per dose and each dose concentration was chosen to be 50% greater than the preceding, for a total of six doses per treatment regime. The lowest dose at which a mouse dies within 30 days of treatment has been shown empirically to provide a good estimate of the LD₅₀ (Deichmann and LeBlanc, 1943).

**Histological studies and tissue pathology**

Mouse tissues at necropsy were fixed in 10% buffered formalin, then dehydrated by successive immersions in graded alcohol solutions. Tissues embedded in paraffin were sectioned at 5 μm and stained with hematoxylin and eosin (both from Sigma) (Prophet et al., 1992). Stained sections were examined using an Eclipse E800 microscope (Nikon, Tokyo, Japan) and images captured with a CCD camera (Optronics, Goleta, CA) using the Molecular Analyst program (Bio-Rad).

**Results**

**Generation of Mgmt null mice**

The Mgmt targeting vector pMT42-ΔE5-NEO-TK (Figure 2B) was constructed as described in Materials and methods and used to target the Mgmt locus in E14 ES cells by homologous recombination. Our strategy was to delete, from Mgmt exon 5, a region encoding the active site cysteine of Mgmt thought to be required for alkyl transfer (Olsson and Lindahl, 1980; Dempel et al., 1985; Santibanez-Koref et al., 1992; Figure 2A). Mgmt heterozygous ES cells were identified by Southern analysis and karyotypically normal cells were injected into mouse blastocysts, generating chimeric mice and germline transmission of the disrupted Mgmt allele. Mgmt +/– offspring were intercrossed and Mgmt null mice were produced in the normal Mendelian ratio. These Mgmt –/– mice developed normally, displaying no obvious phenotypic or pathological abnormalities (data not shown). The structure of the targeted MgmtΔ:neo allele in +/– and –/– Mgmt mice was examined both by Southern (Figure 2C) and PCR (Figure 2D) analysis; Mgmt +/+ , +/– and –/– mice were identified with the expected genotype.

*O*₆-MeG DNA MTase activity levels vary with Mgmt genotype

We examined the levels of *O*₆-MeG DNA MTase activity in the Mgmt +/+ E14 ES cells (used to generate the chimeric mice) and the E14 parental cells. MTase activity in Mgmt +/+ ES cell extracts was reduced to ~60% of the wild-type level (Figure 3A), consistent with targeting one of the Mgmt alleles. For the mice, we examined MTase activity in liver cell extracts (Figure 3B), because liver normally has the highest activity relative to other tissues (Gerson et al., 1986; Moritz et al., 1995). Clearly, MTase activity reflected the Mgmt genotype. MTase activity in Mgmt +/+ liver tissue was ~60% that of wild-type and virtually no activity was found in Mgmt –/– genotypes (Figure 3B), because liver normally has the highest activity for the wild-type and targeted alleles for both the Southern and PCR analysis are indicated at the right. Molecular weight sizes (M) are indicated on the left. The ~2144 bp P1/P3 PCR product expected from the targeted allele was not observed under the conditions employed.

**Ex vivo killing of bone marrow cells by chemotherapeutic alkylating agents**

Bone marrow cells from the femurs of 6- to 12-week-old Mgmt +/+ and –/– mice were harvested and washed twice in 5 ml of α-MEM, then counted. Samples of 10⁶ cells in 4 ml of α-MEM were treated with BCNU, MNU, MMC, STZ, or temozolomide for 1 h at 37°C in 5% CO₂; drug was removed by washing cells twice with α-MEM. Cells, resuspended in α-MEM/20% fetal bovine serum, were mixed with MethoCult™ GF (0.9% methyleneblue saline. After a 120 h incubation in 0.2 ml of serum-containing medium, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added to 0.5 mg/ml and the cells were incubated for an additional 4 h. The medium was replaced with 0.2 ml dimethylsulfoxide and the percentage of metabolically active cells relative to untreated controls was quantified by absorbance at 560 nm. The means and standard deviations determined from four replica samples are displayed; a representative curve from at least three independent experiments is shown for each treatment.
alkylating agents, namely BCNU, MNNG, STZ, and temozolomide for their sensitivity to growth inhibition by a number of agents. Mgmt –/– MEFs are sensitive to chemotherapeutic alkylating agents that do not produce DNA lesions repaired by Mgmt. Indeed, Mgmt activity levels are much lower in bone marrow, one might predict that Mgmt would not play a significant role in protecting this tissue from killing by such agents. However, Mgmt –/– bone marrow cells were extremely sensitive to BCNU, MNU, STZ, and temozolomide (but not to the control agent MMC) compared with cells from wild-type mice (Figure 5A–E). These results illustrate that even low levels of Mgmt can protect cells from the toxic effects of chemotherapeutic alkylating agents.

Mgmt –/– mice are sensitive to chemotherapeutic alkylating agents

Mgmt +/+ and –/– mice were exposed to a single injection of graded doses of the alkylating agents BCNU, MNU, STZ, and MMC in order to determine LD50 values. Table I shows that the Mgmt +/+ mice were considerably more sensitive to BCNU, MNU, and STZ than the wild-type animals, with the difference in LD50 values ranging from ~2-fold for STZ to ~10-fold for MNU. No difference in MMC sensitivity was observed. These results demonstrate that Mgmt plays an essential role in protecting mammals against the toxic effects of several agents used in cancer chemotherapy and suggests that inter-individual variations in MTase repair capacity might be an important variable in chemotherapeutic tolerance.

Chemotherapeutic alkylating agents cause severe ablation of hematopoietic cells in both Mgmt +/+ and –/– mice

The most consistent pathology observed in Mgmt +/+ and –/– mice treated with BCNU, MNU, MMC, and STZ was ablation in bone marrow of the hematopoietic tissues. Tissue sections of sternae revealed hematopoietic compartment spaces devoid of progenitor cells, containing instead only expanded sinuses with mature erythrocytes and small numbers of neutrophils, indicative of myeloaiblation (Figure 6B and D). In contrast, normal hematopoietic compartments of bone marrow from untreated animals had a tightly packed mass of hematopoietic stem cells of several lineages (Figure 6A and C). The atrophy observed following alklylation treatment occurred at much lower drug doses (with the exception of the control agent MMC) in the Mgmt –/– mice than in the wild-type controls (examples from STZ-treated animals are shown in Figure 6). No other consistent pathology was observed following drug treatment. These results demonstrate that the toxicity of alkyl lesions normally repaired by Mgmt is particularly acute in rapidly dividing hematopoietic tissues.
Fig. 4. Growth inhibition of MEFs isolated from Mgmt wildtype (+/+), heterozygous (+/−), or null (−/−) mice treated with (A) BCNU, (B) MNNG, (C) STZ, (D) temozolomide, (E) MMC, and (F) UV light. A representative experiment is shown in each panel; values are reported as means ± SD for four determinations. See text for a discussion of inter-experimental variation in the Mgmt +/− curves.

Table I. Sensitivity of Mgmt +/+ and −/− mice to various alkylating agents

<table>
<thead>
<tr>
<th>Mgmt genotype</th>
<th>LD50 (mg drug/kg body wt)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BCNU</td>
</tr>
<tr>
<td>+/+</td>
<td>39</td>
</tr>
<tr>
<td>+/−</td>
<td>14</td>
</tr>
</tbody>
</table>

Six- to eight-week-old mice were given a single i.p. injection. One mouse was treated per dose and each dose concentration was chosen to be 50% greater than the preceding, for a total of six doses per treatment regime. The lowest dose at which a mouse dies within 30 days of each treatment was taken as the estimate of the 50% lethal dose (LD50) (Deichmann and LeBlanc, 1943). Similar results were obtained in duplicate trials.

Discussion

During a screen of randomly synthesized drugs in the late 1950s by the National Cancer Institute, MNNG was identified as displaying a limited but consistent antitumor activity in mice. At the time, this discovery seemed counter-intuitive, given that MNNG was a known carcinogen. Synthesis and testing of chemical analogs of MNNG identified MNU, which in addition to displaying higher antitumor activity than MNNG, also appeared to cross the blood–brain barrier and to be active against intracerebrally implanted tumors, one of the first chemotherapeutic agents to display such a property. Further nitrosourea congeners, including BCNU, MNNG, and N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea, which are being particularly effective and these agents were subsequently evaluated in clinical trials. The results were disappointing. Although the CNUs remain one of the few classes of drugs effective against central nervous system tumors, their activity is only modest and is associated with significant bone marrow, as well as lung and gastrointestinal, toxicity (Schabel, 1976; Weiss and Issell, 1982; Ludlum, 1997).

A naturally occurring methylnitrosourea derivative, STZ, was also found to have antitumor activity, with less severe associated bone marrow toxicity than the CNUs, and it also entered clinical trials in the 1970s (Weiss, 1982; Ludlum, 1997). More recently, new generations of chemotherapeutic alkylating agents, including temozolomide, have been generated and are being evaluated for their clinical efficacy as antitumor agents (Workman et al., 1992; Abrams et al., 1994; Newlands et al., 1997). Given the wide use of CNUs in the clinical treatment of a variety of cancers and the correlation observed in cultured cells between CNU resistance and DNA MTase activity, the generation of a readily available whole animal model deficient in such activity seemed warranted. We targeted the deletion of a highly conserved amino acid sequence PCHR in the mouse Mgmt gene (Santibanez-Koref et al., 1992), which, judging from other cloned MTases, contains a critical active site cysteine residue (Olsson and Lindahl, 1980; Demple et al., 1985). Mice containing the targeted Mgmt alleles exhibited reduced O6-MeG DNA MTase activity depending upon gene copy number. It is important to note that while MTase activity in Mgmt −/− liver and MEF cells appears to be >0, this may be deceptive, since the activity in Mgmt −/− extracts did not increase with increased protein as it does for authentic MTases (data not shown). However, we cannot exclude the existence of another, separately encoded O6-MeG DNA MTase.

Our results demonstrate that Mgmt plays an important role in the sensitivity of murine hematopoietic tissues to chemotherapeutic alkylating agents, consistent with the results of Sakumi et al. (1997) using MNU, a simple methylating agent that is not used clinically. For both Mgmt +/+ and −/− mice, ablation of bone marrow hematopoietic tissue was the most consistent pathology induced by the alkylating agents tested, albeit at lower doses for the Mgmt −/− mice. Thus, even though the level of O6-MeG DNA MTase in wild-type...
Fig. 5. The clonal survival of bone marrow cells isolated from Mgmt wild-type (+/+), or null (-/-) mice. Cells were treated with (A) BCNU, (B) MNU, (C) MMC, (D) STZ, and (E) temozolomide. A representative experiment is shown in each panel.

Fig. 6. Tissue section of sternebrae from (B) Mgmt wild-type (+/+) and (D) null (-/-) mice displaying atrophy and ablation of hematopoietic cells, respectively, following STZ treatment at the indicated doses. Sections from age-matched untreated (A) Mgmt wild-type (+/+) and (C) null (-/-) sternebrae are shown for comparison. Note the expanded sinusoids in (B) which reflect cell shrinkage and pyknosis and the nearly complete absence of basophilic staining hematopoietic tissues in (D). These findings should be compared with the filled hematopoietic spaces present in the control panels, (A) and (C). The absent tissue in (B) is replaced by expanded sinusoids and in (D) by expanded sinusoids and virtually empty hematopoietic compartments containing mature erythrocytes and serum proteins.
hematopoietic tissues is extremely low relative to other tissues, it nevertheless plays a crucial role in protecting against chemotherapy alkylating agents. It will be interesting to determine how Mgmt knockouts mice transplanted with Mgmt +/+ bone marrow cells respond to these alkylating agents, and these experiments are underway.

In addition, we have shown that O6-MeG DNA MTase plays a critical role in determining the sensitivity of the whole animal to chemotherapy alkylating agents. These results could have important implications for gauging chemotherapeutic drug regimes, given that O6-MeG DNA MTase activity levels probably vary between patients. Indeed, human lymphocyte extracts revealed up to an ~10-fold inter-individual difference in O6-MeG DNA MTase activity (Waldstein et al., 1982a,b; Sagher et al., 1989), these activity levels may vary in response to the chemotherapy itself (Sagher et al., 1988). Such considerations take on added relevance given the demonstration here of the importance of Mgmt in protecting the organism as a whole against the lethal effects of chemotherapy alkylating agents.

In addition to MTase repair, base excision repair is now known to play an important role in protecting cells from the cytotoxic effects of CNU alkylating agents. The Saccharomycosis cerevisiae MAG1-encoded 3-methyladenine DNA glycosylase protects both S.cerevisiae and Escherichia coli against the cytotoxic effects of N(2-chloroethyl)-N-nitrosourea (Matijasevic et al., 1993). Moreover, the mouse 3-methyladenine DNA glycosylase protects murine ES cells against BCNU (Engelward et al., 1996), although it does not appear to be required for alkylation resistance in MEFs (Elder et al., 1998). Such protection may be achieved by the glycosylases preventing the formation of interstrand DNA crosslinks via removal of the crosslink precursor 1,O6-ethanoguanine (formed by an intramolecular condensation of the O6-chloroethyl lesion, the MTase substrate; Ludlum, 1997). The relative importance of DNA MTase and 3methyladenine DNA glycosylase in providing CNU resistance remains to be determined and we are currently generating mice deficient in both activities to investigate this issue.

There now exist a large number of DNA repair-deficient mice generated by targeted homologous recombination and this number is growing rapidly (Friedberg et al., 1997, 1998). Mice deficient in base and nucleotide excision repair, mismatch repair, and recombinational repair already exist and each of these pathways has been implicated in the repair of DNA crosslinks (Siebert and Eisenbrand, 1977; Abril et al., 1996; Aquilina et al., 1998; Chen et al., 1998). Together with the O6-MeG DNA MTase-deficient mouse strain described here, these repair-deficient mouse strains should allow us to determine the relative importance of each repair pathway in protecting cells against chemotherapeutic alkylation agents, information which should prove useful in guiding the clinical use of such agents.

Acknowledgements

We would like to thank Rachel Karlip, Ervin Meluleni and Diane DeMasi for technical assistance. We would also like to acknowledge the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment at the National Cancer Institute for providing BCNU and temozolomide. The animals used in this study were treated and housed in accordance with approved guidelines and supervised by an animal care committee. This research was supported in part by National Cancer Institute (R01-CA55042 and CA75576), Leukemia Society of America (6159-99), and Burroughs Wellcome Toxicology Award grants (L.D.S.), as well as the Dutch Cancer Society (EUR90-20 and EUR94-793), Louis Jeantet Foundation, and Human Frontiers Program grants (J.H.J.H.). B.J.G. was supported by a National Research Service Award Training Grant (T32CA00978-19). J.M.A. is a Leukemia Society of America Fellow. B.P.E. was supported by a Pharmaceutical Manufacturers Association Foundation Advanced Predoctoral Fellowship in Pharmacology/Toxicology and a Graduate Student Research Fellowship Award from the Society of Toxicology (Hoffmann-La Roche Inc.). The research of G.W. has been made possible by a fellowship from the Royal Netherlands Academy of Arts and Sciences.

References


Yarosh, D.B., Barnes, D. and Erickson, L.C. (1986) Transfection of DNA from a chloroethylnitrosourea-resistant tumor cell line (MER+) to a sensitive tumor cell line (MER−) results in a tumor cell line resistant to MNNG and CNU that has increased O6-methylguanine-DNA methyltransferase levels and reduced levels of DNA interstrand crosslinking. Carcinogenesis, 7, 1603–1606.

Received on February 2, 1999; accepted on February 4, 1999

Mgmt knockout mice